Selected article for: "cell surface and host cell"
Author: Ojosnegros, Samuel; Beerenwinkel, Niko
Title: Models of RNA virus evolution and their roles in vaccine design
  • Document date: 2010_11_3
    • ID: 0q928h3b_32
    Snippet: With one exception, the few attempts to bring HIV vaccines to the last phases of clinical trials have been quite disappointing so far. One of the first and most prominent vaccine candidates, the VAXGEN vaccine, was intended to immunize subjects with a recombinant envelope protein of HIV (rgp120) [93, 94] . The envelope protein is located on the surface of HIV and is responsible for the attachment of the virus to the host cell surface receptor [95.....
    Document: With one exception, the few attempts to bring HIV vaccines to the last phases of clinical trials have been quite disappointing so far. One of the first and most prominent vaccine candidates, the VAXGEN vaccine, was intended to immunize subjects with a recombinant envelope protein of HIV (rgp120) [93, 94] . The envelope protein is located on the surface of HIV and is responsible for the attachment of the virus to the host cell surface receptor [95] . Antibodies targeted against this protein could block HIV infection and subsequently block virus entry into cells. During VAXGEN trials, the immunization induced the production of antibodies in vaccinated individuals, but they were unable to control infection or viremia.

    Search related documents:
    Co phrase search for related documents
    • antibody production and cell surface receptor: 1
    • antibody production and clinical trial: 1, 2, 3, 4, 5, 6, 7
    • antibody production and envelope protein: 1, 2, 3
    • antibody production and HIV infection: 1, 2, 3, 4
    • antibody production and HIV surface: 1
    • antibody production and HIV vaccine: 1, 2, 3
    • antibody production and protein target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • antibody production and vaccine candidate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • antibody production and viremia infection: 1, 2, 3
    • antibody production and virus attachment: 1, 2
    • antibody production and virus entry: 1, 2, 3, 4, 5, 6, 7, 8
    • antibody protein target and cell surface: 1
    • antibody protein target and cell surface receptor: 1
    • antibody protein target and protein target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • antibody protein target and vaccine candidate: 1, 2
    • antibody protein target and virus entry: 1, 2, 3
    • cell surface and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cell surface and clinical trial phase: 1, 2, 3, 4, 5, 6
    • cell surface and envelope protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41